MAP2K2 and pancreatic neoplasm: In pancreatic cancer patients, RAS mutations occur in 70–90% patients [19], which results in an abnormal activation of mitogen-activated protein kinase kinase (MEK)1 and MEK2, and subsequent hyperproliferation of pancreatic cancer cells.